Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Outbreak Fingolimod Cardiovascular Side Effects in Relapsing-Remitting Multiple Sclerosis Patient: A Longitudinal Study in an Iranian Population



Abdar M1 ; Ebrahimifar P1 ; Etemadifar M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: ARYA Atherosclerosis Published:2016

Abstract

BACKGROUND: Fingolimod (FTY-720) has shown efficacy in relapsing multiple sclerosis (MS), while some side effects of this drug have been recognized that the most important is cardiovascular side effects. The aim of this study was to evaluate the cardiovascular side effects of FTY-720. However, the effect of fingolimod on cardiac has not been well recognized. This study was designed to evaluate the cardiovascular side effects of fingolimod in relapsing-remitting multiple sclerosis (RRMS) patient in an Iranian population. METHODS: This prospective clinical trial study was performed on 200 RRMS patients. The patients received a single daily oral dose of fingolimod 0.5 mg. During the first 6 hours after the first fingolimod dose, the patients’ vital signs and electrocardiographic traces were continuously monitored. Moreover, the patients followed up over 6 months after receiving fingolimod. RESULTS: The results showed that pulse rate (P < 0.001), systolic blood pressure (BP) (P < 0.001), and diastolic BP (P < 0.001) were decreased significantly during 6 hours after receiving the first dose of fingolimod. The most reduction in vital sign was observed in 3 hours. Arrhythmia, bradycardia, and dizziness were the other complications of fingolimod, which were detected in our study. CONCLUSION: All the side effects such as hypotension and bradycardia were happened in first 3 hours after receiving the fingolimod. Indeed, we advise clinicians to monitor the patients for first 6 hours after initiation of fingolimod to decrease worse side effects. © 2017, Pushpa Publishing House. All rights reserved.
Related Docs
View other Related Docs
1. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
2. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)
3. Comparing the Efficacy of Monthly Cyclophosphamide As Monotherapy Versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis, Journal of Isfahan Medical School (2017)
4. Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients, International Journal of Preventive Medicine (2015)
5. Side Effects of Methylprednisolone Pulse Therapy in Treatment of Multiple Sclerosis, Journal of Isfahan Medical School (2012)
6. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)
7. The Prevalence of Myocardial Infarction Among Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
8. Mitoxantrone-Induced Cardiotoxicity in Patients With Multiple Sclerosis, Archives of Iranian Medicine (2006)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (42)
Masoud Etemadifar (21)
Other Related Docs
9. Possible Regenerative Effects of Fingolimod (Fty720) in Multiple Sclerosis Disease: An Overview on Remyelination Process, Journal of Neuroscience Research (2020)
10. Effect of Mediterranean Diet on Body Mass Index and Fatigue Severity in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of Clinical Trials, Heliyon (2024)
11. Predictors of Treatment Switching in the Big Multiple Sclerosis Data Network, Frontiers in Neurology (2023)
12. Comparison of Prevalence Rates of Restless Legs Syndrome, Self-Assessed Risks of Obstructive Sleep Apnea, and Daytime Sleepiness Among Patients With Multiple Sclerosis (Ms), Clinically Isolated Syndrome (Cis) and Neuromyelitis Optica Spectrum Disorder (Nmosd), Sleep Medicine (2020)
13. Comparative Effectiveness in Multiple Sclerosis: A Methodological Comparison, Multiple Sclerosis Journal (2023)
14. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
15. Tumefactive Rebound of Multiple Sclerosis After the Short-Term Cessation of Fingolimod: A Case Report, Multiple Sclerosis and Related Disorders (2020)
16. Incidence, Prevalence, and Characteristics of Heart Failure Among Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
17. Multiple Sclerosis-Related Fatigue Lacks a Unified Definition: A Narrative Review, Journal of Research in Medical Sciences (2022)
18. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
19. Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient With Multiple Sclerosis Treated With Interferon-Beta, Journal of Isfahan Medical School (2018)
20. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
21. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
22. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
23. The Prevalence of Restless Legs Syndrome (Rls) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis—An Update, Neurological Sciences (2023)
24. Incidence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Treated With Fingolimod: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
25. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
26. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
27. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
28. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
29. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
30. Islamic Fasting and Multiple Sclerosis, BMC Neurology (2014)
31. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
32. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
33. Evaluating the Effect of Adding Fish Oil to Fingolimod on Tnf-Α Il1β Il6, and Ifn-Γ in Patients With Relapsing-Remitting Multiple Sclerosis: A Double-Blind Randomized Placebo-Controlled Trial, Clinical Neurology and Neurosurgery (2017)
34. Atherosclerosis and Multiple Sclerosis: An Overview on the Prevalence of Risk Factors, Multiple Sclerosis and Related Disorders (2022)
35. Serum Lipids and Cognitive Outcomes in Multiple Sclerosis; a Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2024)
36. False Diagnosis in Multiple Sclerosis, Pakistan Journal of Medical Sciences (2013)
37. Increased Expression of Lymphocyte Activation Gene-3 by Regulatory T Cells in Multiple Sclerosis Patients With Fingolimod Treatment; [Multiple Sikleroz Hastalarinda Fingolimod Tedavisi Sonucu Duzenleyici T Hucrelerinde Lenfosit Aktivasyon Gen-3 Ekspresyonunda Artis], Turkish Journal of Immunology (2019)
38. Modified Mediterranean Diet V. Traditional Iranian Diet: Efficacy of Dietary Interventions on Dietary Inflammatory Index Score, Fatigue Severity and Disability in Multiple Sclerosis Patients, British Journal of Nutrition (2022)
39. Mitoxantrone Reduced Disability in Iranian Patients With Multiple Sclerosis, Archives of Iranian Medicine (2007)
40. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
41. Multiple Sclerosis and the Incidence of Venous Thromboembolism: A Systematic Review and Meta-Analysis, Journal of Thrombosis and Thrombolysis (2023)
42. Seasonal and Monthly Variation in Multiple Sclerosis Relapses: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2022)
43. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
44. Worldwide Prevalence of Neuromyelitis Optica Spectrum Disorder (Nmosd) and Neuromyelitis Optica (Nmo): A Systematic Review and Meta-Analysis, Neurological Sciences (2023)
45. Effects of Rivastigmine on Memory and Cognition in Multiple Sclerosis, Canadian Journal of Neurological Sciences (2008)
46. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis in the United Kingdom, Journal of Medical Economics (2024)
47. Design, Synthesis, Bioactivity Analyses, and Molecular Docking Study of Triazine-Tyrosine Based Derivatives As Drugs Like Fingolimod for Treatment of Multiple Sclerosis, Polycyclic Aromatic Compounds (2024)
48. Potential of Modified Mediterranean Diet to Improve Quality of Life and Fatigue Severity in Multiple Sclerosis Patients: A Single-Center Randomized Controlled Trial, International Journal of Food Properties (2020)
49. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
50. Short-Term Safety of Pulse Steroid Therapy in Multiple Sclerosis Relapses, Clinical Neuropharmacology (2013)